Vivacitas Oncology to present AR-67 at the Biotech Showcase Investor Conference

WALNUT CREEK, CALIFORNIA, US, January 10, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately held clinical stage biopharmaceutical company focused on tough–to–treat cancers, today announced it will present at the 2022 Biotech Showcase conference with an on-line presentation. 

Mark Suseck, Vivacitas CEO & Director, will present an overview of the company, its lead compound (AR-67), and clinical development plans. Mr. Suseck stated, “We look forward to participating in this year’s Showcase and sharing an update on our efforts to deliver potential new treatment options for oncology patients.” 

Biotech Showcase is an investor and networking conference focused on innovative private and micro-mid-cap biotechnology companies.

Presentation details can be found below:

Title 

Vivacitas Oncology Inc.

Presenter

Mark Suseck

Date

Tuesday, January 11, 2022

Time

3:15 PM (PST) / 6:15 PM (EST)

For registration, click here.

ABOUT VIVACITAS ONCOLOGY:

Vivacitas Oncology is a private clinical-stage biopharmaceutical company focused on tough-to-treat cancers.  It originated with the vision of Dr. Joseph Rubinfeld (co-founder of Amgen) and Infusion 51a, LP to transform select chemotherapies beyond their initial potency, toxicity, stability, and/or pharmacokinetics challenges and unlock maximum treatment and tolerability potential. Through an enduring spirit, Vivacitas continues to apply clarity, tenacity, and vision in our fight against aggressive cancers and our pursuit of new treatment options for patients and their families worldwide.

For further information please visit www.vivaoncology.com or Elise@vivaoncology.com

References

1. Novel silatecan displays high lipophilicity, improved blood stability and potent
anticancer activity. Bom D, et al J Med Chem 2000; 43:3970-3980

2. Silatecan DB-67 is a novel DNA Topo-1 targeted radiation sensitizer: Chen AY. Mol
Cancer Ther 2005; 4(2): 317-24.

3. Phase I study publication: Arnold SM, et al. Clin Cancer Res. 2010;6:673-680

4. Phase II study publication (abstract): Kumthekar P, et al. SNO 2019. Poster ACTR-40,
published in Neuro-Oncology(https://academic.oup.com/neuro-oncology)

5. Ubiquitin-dependent Destruction of Topoisomerase I Is
Stimulated by the Antitumor Drug Camptothecin*, Desai et al. The Journal of Biological Chemistry, Vol. 272, No. 39, Issue of September 26, pp. 24159–24164, 1997.  https://www.jbc.org

6. Metabolic Pathways of the Camptothecin Analog AR-67, Horn et al. Drug Metabolism and Disposition, Vol. 39, No. 4, 37390/3672838, 2011. https://dmd.aspetjournals.org